Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Physician perspectives: Mike Sevilla

Kicking off our new physician series, family physician Mike Sevilla who acts as a social media ambassador to the Family Medicine Physician community shares his thoughts on how beneficial social media is to him and how other physicians can become engaged. Mike Sevilla, a family physician, was formerly known as doctor anonymous and currently blogs at the site ‘Family medicine rocks’. Through his blogs...

Articles

Pharma vs. physician: how data can relieve the headache (par...

In part one of a two-part article Kabir Shahani teaches how the right data can be used to gain a better insight into your target audience and achieve a competitive advantage. As a founder of a healthcare software company, I hear leaders across the healthcare industry – from creative services companies to pharma executives…

Articles

The EU generics market: a Greek perspective

Rebecca Aris speaks with the head of the R&D department for generic product development at Genepharm for his insights into the current trends in the EU generics market. Ahead of his speaking engagement at the Generics & Biosimilars summit 2012, Deepak shares his insights...

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.